Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
22 hedge funds and large institutions have $33.1M invested in Sophiris Bio, Inc. in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 24 → 22 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
18% less capital invested
Capital invested by funds: $40.6M → $33.1M (-$7.51M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.01M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$422K |
| 3 |
BIM
Baldwin Investment Management
West Conshohocken,
Pennsylvania
|
+$44.4K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
+$44.4K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$6.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$690K |
| 2 |
DM
Deerfield Management
New York
|
-$578K |
| 3 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
-$148K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$51K |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
-$35K |
SPHS Hedge Fund Activity: Q4 2013 in Review
22 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q4 2013, worth a combined $33.1M — down 18% from $40.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SPHS and 5 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.
The largest buyer was Palo Alto Investors, adding an estimated $1.01M. The largest seller was Citadel Advisors, exiting entirely with an estimated $690K sold.
- 22 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q4 2013, down from 24 in Q3 2013.
- Funds reported $33.1M of Sophiris Bio, Inc. stock for Q4 2013, down 18% quarter-over-quarter.
- 5 funds opened new Sophiris Bio, Inc. positions in Q4 2013 and 6 closed out, a net change of -1 holder.
- The largest Sophiris Bio, Inc. buyer in Q4 2013 was Palo Alto Investors, an estimated $1.01M added.
- The largest Sophiris Bio, Inc. seller in Q4 2013 was Citadel Advisors, an estimated $690K sold.
Based on aggregated 13F filings for Q4 2013.